Categories AlphaGraphs, Earnings, LATEST, Other Industries

ImmunoGen’s Q2 results beat estimates

ImmunoGen Inc. (NASDAQ: IMGN) reported better-than-expected results for the second quarter of 2019, sending the stock soaring 13.5% in premarket hours on Friday. Analysts had forecast a loss of $0.33 per share on revenue of $9.4 million.

Total revenue jumped nearly 67% to $15.5 million from the same period last year. The results included $10.4 million in non-cash royalty revenues. License and milestone fees amounted to $5.1 million in the quarter.   

Net loss was $43.4 million, or $0.29 per share, compared to $41.6 million, or $0.31 per share, in the prior-year period.

ImmunoGen cash reserves and operating loss quarterly trend

Operating expenses rose to $56.6 million from $48 million last year, mainly due to a $19.3 million restructuring charge resulting from operational changes. R&D expenses fell to $28.6 million from $38.7 million, mainly due to lower personnel expenses.   

For the full year of 2019, the company expects revenues of $40-45 million and operating expenses of $175-180 million.

During the second quarter, ImmunoGen accelerated enrollment in the FORWARD II mirvetuximab plus bevacizumab combination cohort in ovarian cancer patients for whom a non-platinum-based regimen would be an appropriate next therapy. The company expects to complete enrollment in the FORWARD II mirvetuximab plus bevacizumab combination cohort in the third quarter.

ImmunoGen plans to initiate the Phase 3 registration study of mirvetuximab as a monotherapy for women with FRα-high, platinum-resistant ovarian cancer by the end of this year and also to commence enrollment in the IMGN632 combination and single-agent MRD+ Phase 2 cohorts.

ImmunoGen had $239.8 million in cash and cash equivalents as of June 30, 2019. Capital expenditures were $2.4 million for the first half of 2019.

ImmunoGen’s stock has dropped 49% year-to-date and 4% in the past three months.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many


Add Comment
Viewing Highlight